Precision BioSciences Presents Promising Phase 1 Data for HBV Gene Editing Therapy

Precision BioSciences, Inc. announced new Phase 1 clinical data from its ELIMINATE-B study of PBGENE-HBV, an in vivo gene editing therapy for chronic hepatitis B. The data, to be presented at The Liver Meeting® 2026, demonstrate cccDNA elimination and potential to drive viral cure, with 100% of evaluable patients achieving undetectable pgRNA at the expected go-forward dose.